Skip to main content
. 2018 Jan 29;3(1):e000288. doi: 10.1136/esmoopen-2017-000288

Table 5.

Response

n=22 Percentage
Objective response* 10 45
 Complete response 0 0
 Partial response 10 45
Stable disease 6 27
Progressive disease 5 23
Not evaluable 1 5

*Responses were evaluated in patients with postsurgical recurrence and advanced non-small cell lung cancer with target lesions.

†95% CI 24.4% to 67.8%.